Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Lubar & Co., Inc HNRG Hallador Energy Co 13D/A 11.49% 2y
Shufu Li PSNY Polestar Automotive Holding UK PLC 13D/A 88.3% 2y
Monte M. Brem STEP StepStone Group Inc. 13D/A 48.3% 2y
Benjamin G. Wolff PDYN Palladyne AI Corp. 13D/A 6.1% 2y
Ephraim G Fields NURO NeuroMetrix, Inc. Common Stock 13D 9.3% 2y
HGGC Fund IV GP, Ltd. UPLD Upland Software, Inc. 13D/A 20.19% 2y
Krensavage Asset Management, LLC ENTA Enanta Pharmaceuticals Inc 13G 5.1% 2y
GAMCO INVESTORS, INC. ET AL HARP Harpoon Therapeutics, Inc. Common Stock 13D 4.03% 2y
Klaus Umek CRTO Criteo S.A. 13D 5.6% 2y
Lytton, Laurence W. AZTR Azitra, Inc. 13G 5.8% 2y
Phillip Frost, M.D. BCDA BioCardia, Inc. 13D/A 6.1% 2y
INGALLS & SNYDER LLC HYFT MindWalk Holdings Corp. 13G 5.01% 2y
Union Square Park Capital Management, LLC REED Reed's, Inc. 13D/A 17.98% 2y
John Michael DiMaio MDAI Spectral AI, Inc. 13D/A 15.3% 2y
Undavia Nilesh EAF Graftech International Ltd 13D/A 5.74% 2y
Walleye Capital LLC AQUC Aquaron Acquisition Corp. 13G 7.82% 2y
AMERIPRISE FINANCIAL INC PIII P3 Health Partners Inc. 13G/A 4.72% 2y
Walleye Capital LLC ACU Acme United Corp 13G/A 0% 2y
Alpha Intelligence Enterprises Ltd APLM Apollomics Inc. 13G 8.66% 2y
Patient Capital Management, LLC PGEN Precigen, Inc. 13G/A 6.42% 2y
Bitfury Top HoldCo B.V. CIFR Cipher Digital Inc. 13D/A 46.2% 2y
CoyCo GP, L.L.C. RCM R1 RCM Inc. Common Stock 13D/A 32.4% 2y
COLUMN GROUP L P NGM NGM Biopharmaceuticals, Inc. Common Stock 13D/A 26.7% 2y
Findell Capital Partners LP OPRT Oportun Financial Corp 13D/A 6.5% 2y
Yoda PLC CCEC Capital Clean Energy Carriers Corp. 13D/A 25.7% 2y
Indaba Capital Management, L.P. ONTF ON24 INC. 13D/A 10.2% 2y
Starboard Value LP FTRE Fortrea Holdings Inc. 13D/A 6.9% 2y
Cano Health, Inc. MSPR MSP Recovery, Inc. 13D/A 32% 2y
Antofagasta plc BVN Buenaventura Mining Co Inc 13D/A 18.9% 2y
Christopher Scott Ginieczki, as Personal Representative of the Estate of Geoffrey S. M. Hedrick IA Innovative Solutions & Support Inc 13D/A 6.09% 2y
Edward S. Lampert SRG Seritage Growth Properties 13D/A 24.1% 2y
GLOBAL VALUE INVESTMENT CORP. RMCF Rocky Mountain Chocolate Factory, Inc. 13D/A 17.93% 2y
Michael P. Nieri UHG United Homes Group, Inc. 13D/A 76.98% 2y
RA CAPITAL MANAGEMENT, L.P. LRMR Larimar Therapeutics, Inc. 13G 9.5% 2y
Venrock Healthcare Capital Partners III, L.P. ENGN enGene Therapeutics Inc. 13G 5.9% 2y
MILLENNIUM MANAGEMENT LLC LAB Standard Biotools Inc. 13G 5.2% 2y
Slotting RemainCo Limited Partnership FET Forum Energy Technologies, Inc. 13G/A 4.3% 2y
CQS (UK) LLP URG Ur-Energy Inc 13G 5.27% 2y
Palantir Technologies Inc. SRFM Surf Air Mobility Inc. 13G 7.1% 2y
ADAGE CAPITAL PARTNERS GP, L.L.C. KALV KalVista Pharmaceuticals, Inc. 13G 6.87% 2y
Ezra Friedberg PTHS Pelthos Therapeutics Inc. 13D 9.5% 2y
Alpha 18 Inc. AZTR Azitra, Inc. 13G/A 4.2% 2y
F. Hurst Lin (“Lin”) AUGX Augmedix, Inc. Common Stock 13D/A 0.6% 2y
ADAGE CAPITAL PARTNERS GP, L.L.C. SOC Sable Offshore Corp. 13G 6.58% 2y
RS Fund LP NURO NeuroMetrix, Inc. Common Stock 13D 14.4% 2y
Jonas Grossman ATCH AtlasClear Holdings, Inc. 13G 9.99% 2y
Landy Toth AMIX Autonomix Medical, Inc. 13D 10.8% 2y
Phoenix Financial Ltd. CSTE Caesarstone Ltd. 13G/A 11.38% 2y
Mariano Gomide de Faria VTEX Vtex 13G/A 31.7% 2y
Cowen Financial Products LLC STOK Stoke Therapeutics, Inc. 13G/A 8.3% 2y